Systemic Screening for Hereditary Colorectal Cancer in China

• Conditions: Hereditary Colorectal Cancer

• Registration Number: NCT03365986
• Lead Sponsor: Sun Yat-sen University

Brief Summary

The purpose of the this study is to determine the prevalence of germline cancer susceptibility gene mutation among Chinese population, and to find best ways to screen patients with colorectal cancer in China. To accomplish this objective, the investigators will establish a large sample database of hereditary colorectal cancer related information using multigene panel testing based on Next-Generation Sequencing.

Detailed Description

Hereditary factors play a very important role in colorectal cancer risk. Identification of the germline cancer gene mutation at the time of colorectal cancer presentation has significant implications for the patients and families, as it directs follow up and clinical options. Professional guidelines recommend patients with colorectal cancer receive a phenotype-driven genetic testing strategies. For example，Lynch syndrome was identified in 2%-4% of patients with CRC using micro-satellite instability (MSI) or DNA mismatch repair (MMR) protein immunohistochemistry (IHC) tumor testing in preselected patients for germline MMR gene testing. However, there is few of clinical characteristics or germline gene mutation data from Chinese population. With the advent of next-generation sequencing (NGS), genetic testing for hereditary CRC has shifted from phenotype-specific single gene assessment to broad panels providing simultaneous assessment of multiple genes implicated in various hereditary cancer syndromes. This study plans to screen and establish a database of 500 consecutive newly diagnosed patients with CRC using multigene panel testing based on Next-Generation Sequencing. The purpose of this study is to:

1. Determine the prevalence of hereditary colorectal cancer and spectrum of germline cancer gene mutation among Chinese population.

2. Evaluate the cost-effectiveness and optimize the design of multigene panel testing.

3. Establish a statewide screening model for hereditary colorectal cancer.

Study Timeline

• Study First Submitted: 2017-11-26
• Status Verified: 2017-12
• Study First Submitted QC: 2017-12-03
• Study First Posted: 2017-12-08
• Last Update Submitted: 2017-12-09
• Last Update Posted: 2017-12-12
• Study Start: 2018-01-01
• Primary Completion: 2018-03-31
• Study Completion: 2018-03-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Newly diagnosed with colorectal adenocarcinoma (all stages) patients. For individuals who are old than 70 years old should meet the revised Bethesda Guidelines or polyposis syndromes testing criteria.
2. Agree to provide related information.

Exclusion Criteria

1. Individuals who are under the age of 18.
2. Individuals who refuse to test.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of hereditary colorectal cancer	3 months	Through genetic testing for germline cancer susceptibility gene mutations among 500 consecutive patients with colorectal cancer using multigene panel testing based on Next-Generation Sequencing

Secondary Outcome Measures

Name	Time	Method
cost-effect for hereditary colorectal cancer screening	3 months	The direct cost of multigene panel testing or the traditional phenotype-specific single gene testing for hereditary colorectal cancer were estimated, and cost-effect analysis were be done between this two strategies

Trial Locations

Locations (1)

651 Dongfeng Road East; 🇨🇳 Guangzhou, Guangdong, China